March 27, 2018 / 12:11 PM / 25 days ago

BRIEF-Avexis Gene Therapy Awarded Sakigake Designation For Spinal Muscular Atrophy Type 1

March 27 (Reuters) - Avexis Inc:

* AVEXIS GENE THERAPY AWARDED SAKIGAKE DESIGNATION FOR SPINAL MUSCULAR ATROPHY TYPE 1

* AVEXIS INC - DESIGNATION WAS BASED ON DATA FROM PHASE 1 CLINICAL TRIAL OF CO’S PROPRIETARY GENE THERAPY​

* AVEXIS INC - ‍JAPAN’S MINISTRY OF HEALTH, LABOUR AND WELFARE AWARDED INITIAL PRODUCT CANDIDATE, AVXS-101, SAKIGAKE FOR TREATMENT OF SMA TYPE 1​ Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below